Drug Profile


Alternative Names: CAST; CST; MDL 26190

Latest Information Update: 20 Feb 2007

Price : $50

At a glance

  • Originator Anutech
  • Developer Anutech; Nonindustrial source
  • Class Antihyperglycaemics; Antivirals; Indolizines; Small molecules
  • Mechanism of Action Alpha-glucosidase inhibitors; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Diabetes mellitus; Transplant rejection

Most Recent Events

  • 20 Feb 2007 Discontinued - Preclinical for Transplant rejection in Australia (unspecified route)
  • 26 Jul 2001 No-Development-Reported for Transplant rejection in Australia (Unknown route)
  • 21 Aug 1997 Data have been added to the pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top